LAUNXP BIOMEDICAL CO., LTD.
Update：2025/12/03
Industries
Main Industry
Biotechnology
Main Product/Service
505(b)(1) New Drug Development: Exploring new indications by repurposing approved drugs for chronic diseases in cancer treatment.
505(b)(2) Drug Repositioning: Utilizing FDA-approved drugs to identify their anticancer mechanisms, thereby shortening development timelines and reducing costs.
Virus-Like Particles (VLPs) and Nanodrug Carriers: Developing precision drug delivery systems to enhance therapeutic efficacy.
505(b)(2) Drug Repositioning: Utilizing FDA-approved drugs to identify their anticancer mechanisms, thereby shortening development timelines and reducing costs.
Virus-Like Particles (VLPs) and Nanodrug Carriers: Developing precision drug delivery systems to enhance therapeutic efficacy.
Founded Year
2015
Unified Business No.
54823306
Status
Active
Number of Employees
0
Total Paid-in
Capital
693,996,359 (NT$)
Location of Company
Taiwan
, Hsinchu County
Exit Status
Emerging Stock Exchange(2024)
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
LaunXP Biomedical Co., Ltd., founded in 2015, focuses on the research and development of novel cancer therapies, dedicated to creating innovative treatments that improve patients’ quality of life.
